Alnylam Pharma (ALNY) Price & Analysis

Compare

1,239 Followers

ALNY Stock Chart & Stats

Day’s Range― - ―

52-Week Range$146.79 - $304.39

Previous CloseN/A

Volume78.96K

Average Volume (3M)955.27K

Market Cap

$37.83B

Enterprise Value$33.03B

Total Cash (Recent Filing)$2.63B

Total Debt (Recent Filing)$1.30B

Price to Earnings (P/E)―

Beta1.21

Next Earnings

Jul 31, 2025

EPS Estimate

-0.67

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.44

Shares Outstanding130,388,400

10 Day Avg. Volume899,287

30 Day Avg. Volume955,273

Financial Highlights & Ratios

PEG Ratio-32.76

Price to Book (P/B)282.13

Price to Sales (P/S)0.00

P/FCF Ratio-434.40

Enterprise Value/Market Cap0.87

Enterprise Value/Revenue3.66

Enterprise Value/Gross Profit16.35

Enterprise Value/Ebitda-97.68

Forecast

1Y Price Target

$327.95

Price Target Upside13.05% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering23

Alnylam Pharma News

See All News >

Bulls Say, Bears Say

Bulls Say

EfficacyAmvuttra treatment reduced urgent heart failure visits by 46% in the overall population.

Market GrowthRapid growth in diagnosis of ATTR-CM is underscored by Dr. Santos's experience, which aligns with expectations for continued strong market growth.

Regulatory AdvantageFDA approved Amvuttra for TTR-CM to reduce cardiovascular mortality, cardiovascular hospitalizations, and urgent heart failure visits, setting it apart from other treatments.

Bears Say

Market CompetitionKey debates on Amvuttra market share in 1L/switch patients and physician adoption of the buy-and-bill model remain to be answered over the next 2-3 quarters.

Financials

Income Statement >

Options Prices

Detailed Option Prices >

Ownership Overview

0.42% Insiders

48.30% Mutual Funds

0.09% Other Institutional Investors

35.67% Public Companies and Individual Investors

Detailed Ownership Overview >

ALNY FAQ

What was Alnylam Pharmaceuticals’s price range in the past 12 months?

Alnylam Pharmaceuticals lowest stock price was $146.79 and its highest was $304.39 in the past 12 months.

What is Alnylam Pharmaceuticals’s market cap?

Alnylam Pharmaceuticals’s market cap is $37.83B.

When is Alnylam Pharmaceuticals’s upcoming earnings report date?

Alnylam Pharmaceuticals’s upcoming earnings report date is Jul 31, 2025 which is in 63 days.

How were Alnylam Pharmaceuticals’s earnings last quarter?

Alnylam Pharmaceuticals released its earnings results on May 01, 2025. The company reported -$0.44 earnings per share for the quarter, beating the consensus estimate of -$0.89 by $0.45.

Is Alnylam Pharmaceuticals overvalued?

According to Wall Street analysts Alnylam Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Alnylam Pharmaceuticals pay dividends?

Alnylam Pharmaceuticals does not currently pay dividends.

What is Alnylam Pharmaceuticals’s EPS estimate?

Alnylam Pharmaceuticals’s EPS estimate is -0.67.

How many shares outstanding does Alnylam Pharmaceuticals have?

Alnylam Pharmaceuticals has 130,388,400 shares outstanding.

What happened to Alnylam Pharmaceuticals’s price movement after its last earnings report?

Alnylam Pharmaceuticals reported an EPS of -$0.44 in its last earnings report, beating expectations of -$0.89. Following the earnings report the stock price went down -3.081%.

Which hedge fund is a major shareholder of Alnylam Pharmaceuticals?

Currently, no hedge funds are holding shares in ALNY

Alnylam Pharma Stock Smart Score

Outperform

Fundamentals

Return on Equity

-414.62%

Trailing 12-Months

Asset Growth

10.18%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics based on RNA interference (RNAi). The company operates in the healthcare sector and specializes in the development of therapies for genetically defined diseases. Alnylam's core products are RNAi-based medicines designed to treat a variety of conditions, including rare genetic diseases, cardio-metabolic diseases, and infectious diseases.

ALNY Company Deck

ALNY Earnings Call

Q1 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call reflected a generally positive trajectory for Alnylam Pharmaceuticals, characterized by strong revenue growth and successful product launches. Despite some uncertainties related to regulatory policies and increased R&D expenses, the company's strategic focus on TTR leadership and sustainable financial performance supports a positive outlook.Read More>

ALNY Revenue Breakdown

67.90% Net product revenues

29.87% Net revenues from collaborations

2.22% Royalty revenue

ALNY Stock 12 Month Forecast

Average Price Target

$327.95

▲(13.05%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"147":"$147","324":"$324","501":"$501","235.5":"$235.5","412.5":"$412.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":500,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$500.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":327.95,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$327.95</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":245,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$245.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[147,235.5,324,412.5,501],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Nov<br/>2024","9":"Feb<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,255.13,273.9661538461538,292.8023076923077,311.6384615384615,330.4746153846154,349.3107692307692,368.14692307692303,386.9830769230769,405.8192307692308,424.6553846153846,443.4915384615384,462.3276923076923,481.1638461538461,{"y":500,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,255.13,260.73153846153843,266.33307692307693,271.93461538461537,277.53615384615387,283.1376923076923,288.73923076923074,294.34076923076924,299.9423076923077,305.5438461538462,311.1453846153846,316.74692307692305,322.34846153846155,{"y":327.95,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,255.13,254.35076923076923,253.57153846153847,252.7923076923077,252.0130769230769,251.23384615384614,250.45461538461538,249.67538461538462,248.89615384615385,248.1169230769231,247.3376923076923,246.55846153846153,245.77923076923076,{"y":245,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":149.96,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":148.43,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":243.32,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":268.61,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":262.69,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":276.06,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 62,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":273.91,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":253.01,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":235.31,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":271.31,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":246.75,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 56,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":255.76,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 57,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":255.13,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 56,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >